Adial Pharmaceuticals (ADIL) Price & Analysis

Compare

600 Followers

ADIL Stock Chart & Stats

$0.32

-$0.03(-2.80%)

At close: Jan 08 4:00 PM EST

$0.32

-$0.03(-2.80%)

Day’s Range― - ―

52-Week Range$0.22 - $1.30

Previous CloseN/A

Volume36.45K

Average Volume (3M)746.19K

Market Cap

$7.10M

Enterprise Value-$2.70M

Total Cash (Recent Filing)$4.61M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Mar 26, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding21,828,215

10 Day Avg. Volume779,793

30 Day Avg. Volume746,186

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)4.62

Price to Sales (P/S)0.00

P/FCF Ratio-2.71

Enterprise Value/Market Cap-0.38

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit9.59K

Enterprise Value/Ebitda0.34

Forecast

1Y Price Target

$1.50

Price Target Upside368.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker ValidationAdial now has a validated biomarker test for its target sub-population, representing an important milestone for AD04 beyond just Phase 3.

Collaboration And PartnershipsAdial announced a collaboration agreement with Genomind following successful analytical validation of a cheek swab collection method for testing patients both in clinical and commercial applications.

Regulatory ApprovalWith FDA alignment secured following the positive End-of-P2 meeting in September, Adial is now advancing preparations for its registrational P3 study.

Bears Say

Financial PerformanceAdial reported 3Q25 results with a net loss of ($1.8M) and ended the period with $4.6M in cash on the balance sheet.

Funding NeedsThe company still needs additional capital or partnership to fund the study, despite having $5.9M in cash reported at the end of 2Q25, which should provide operating capital into 2Q26.

Adial Pharmaceuticals News

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

Adial Pharmaceuticals (ADIL) announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of...

8d ago

ADIL

Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

Cash and cash equivalents were $4.6 million as of September 30, 2025, compared to $5.9 million as of...

20d ago

ADIL

Adial Pharmaceuticals Secures $2.86M Through Warrant Agreement

Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On November 25, 2025, Adial Pharmaceuticals entered into a...

3d ago

ADIL

Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Adial Pharmaceuticals. The associated price target...

16d ago

ADIL

Is ADIL a Buy, Before Earnings?

Adial Pharma (ADIL) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street analysts...

19d ago

ADIL

Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Adial Pharmaceuticals and keeping the price target...

2M ago

ADIL

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

Adial Pharmaceuticals (ADIL) announced the successful completion of the analytical validation of a cheek swab collection method for...

2M ago

ADIL

CoreWeave initiated, Instacart downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

FCX

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

Maxim upgraded Adial Pharmaceuticals (ADIL) to Buy from Hold with a $1.50 price target Published first on TheFly...

2M ago

ADIL

Adial Pharmaceuticals Advances AD04 with FDA Support

Adial Pharmaceuticals ( ($ADIL) ) has shared an update. On September 16, 2025, Adial Pharmaceuticals announced receiving final...

3M ago

ADIL

Adial announces receipt of final meeting minuts from EOP2 meeting with FDA

Adial Pharmaceuticals (ADIL) announced receipt of the final meeting minutes from its End of Phase 2, EOP2, Meeting...

3M ago

ADIL

Adial Pharmaceuticals Granted Nasdaq Compliance Extension

An update from Adial Pharmaceuticals ( ($ADIL) ) is now available. On September 2, 2025, Adial Pharmaceuticals received...

3M ago

ADIL

Adial granted a 180 calendar day extension by Nasdaq to regain compliance

Adial Pharmaceuticals (ADIL) announced that it has been granted a 180 calendar day extension from The Nasdaq Stock...

3M ago

ADIL

Adial encouraged by U.S. Senate support for extended AUD trial endpoints

Adial Pharmaceuticals (ADIL) “applauded” recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance...

4M ago

ADIL

ADIL FAQ

What was Adial Pharmaceuticals Inc’s price range in the past 12 months?

Adial Pharmaceuticals Inc lowest stock price was $0.22 and its highest was $1.30 in the past 12 months.

What is Adial Pharmaceuticals Inc’s market cap?

Adial Pharmaceuticals Inc’s market cap is $7.10M.

When is Adial Pharmaceuticals Inc’s upcoming earnings report date?

Adial Pharmaceuticals Inc’s upcoming earnings report date is Mar 26, 2026 which is in 111 days.

How were Adial Pharmaceuticals Inc’s earnings last quarter?

Adial Pharmaceuticals Inc released its earnings results on Nov 14, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.137 by $0.057.

Is Adial Pharmaceuticals Inc overvalued?

According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adial Pharmaceuticals Inc pay dividends?

Adial Pharmaceuticals Inc does not currently pay dividends.

What is Adial Pharmaceuticals Inc’s EPS estimate?

Adial Pharmaceuticals Inc’s EPS estimate is -0.09.

How many shares outstanding does Adial Pharmaceuticals Inc have?

Adial Pharmaceuticals Inc has 21,828,215 shares outstanding.

What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?

Adial Pharmaceuticals Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.137. Following the earnings report the stock price went up 1.881%.

Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ADIL

Company Description

Adial Pharmaceuticals Inc

Adial Pharmaceuticals (ADIL) is a clinical-stage biopharmaceutical company specializing in developing therapeutic treatments for addiction and related disorders. Headquartered in the United States, the company's core product focuses on a genetically targeted medication designed to combat alcohol use disorder (AUD). Adial leverages its expertise in genetics and addiction treatment to develop innovative solutions aimed at improving patient outcomes in the field of addiction medicine.

Adial Pharmaceuticals (ADIL) Earnings & Revenues

Historic Earnings Reports

ADIL Stock 12 Month Forecast

Average Price Target

$1.50

▲(368.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.349,0.43753846153846154,0.5260769230769231,0.6146153846153846,0.7031538461538461,0.7916923076923077,0.8802307692307692,0.9687692307692307,1.0573076923076923,1.1458461538461537,1.2343846153846154,1.3229230769230769,1.4114615384615383,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.349,0.43753846153846154,0.5260769230769231,0.6146153846153846,0.7031538461538461,0.7916923076923077,0.8802307692307692,0.9687692307692307,1.0573076923076923,1.1458461538461537,1.2343846153846154,1.3229230769230769,1.4114615384615383,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.349,0.43753846153846154,0.5260769230769231,0.6146153846153846,0.7031538461538461,0.7916923076923077,0.8802307692307692,0.9687692307692307,1.0573076923076923,1.1458461538461537,1.2343846153846154,1.3229230769230769,1.4114615384615383,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.02,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.981,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.785,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.656,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.695,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.455,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.376,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.349,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >